在肺状细胞癌中准mTORC2通过PSGL-1-VISTA轴提高了通过PSGL-1-VISTA轴的抗瘤免疫力
Verra M Ngwa1, Yoonha Hwang1, Wenqiang Song1,2
1Department of Medicine, Division of Rheumatology, Vanderbilt University Medical Center, Nashville, TN, USA.
Cancer gene therapy
|July 10, 2025
概括
准mTORC2通路可以改善肺状癌 (LUSC) 的免疫反应. 这项研究揭示了mTORC2抑制减少瘤生长和增强T细胞活性,为LUSC患者提供新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 肺状癌 (LUSC) 与肺腺癌不同,缺乏向治疗方法.
- 目前的免疫疗法对LUSC的疗效有限.
- 在LUSC免疫中mTORC2信号通路的作用尚未被探索.
研究的目的:
- 研究mTORC2信号通路作为LUSC.中的治疗标.
- 确定mTORC2向对LUSC的抗瘤免疫反应的影响.
- 探索mTORC2,低氧和LUSC中的免疫逃避之间的关系.
主要方法:
- 对LUSC患者瘤中的遗传变化的分析.
- 在体内研究中使用LUSC.小鼠模型进行了体内研究.
- 对缺乏mTORC2的LUSC细胞进行转录基因分析.
- 测量乳酸盐水平和瘤微环境的酸度.
- 调查PSGL-1表达及其对HIF-2α的依赖.
- 评估CD8+T细胞激活和对抗VISTA免疫疗法的反应.
主要成果:
- 在LUSC中,mTORC2通路中的遗传变化很普遍.
- 向mTORC2在小鼠模型中抑制LUSC瘤的生长.
- mTORC2 缺乏会减少糖分和缺氧相关基因的表达,降低瘤的酸度.
- 缺乏mTORC2的LUSC细胞通过依赖HIF-2α的机制显示PSGL-1表达的减少.
- 在LUSC中存在HIF-2α和PSGL-1之间的正相关性,但不是LUAD.
- mTORC2 损失增强了 CD8+ T 细胞的激活; 抗VISTA 疗法只有在完整的 mTORC2.2 时才有效.
结论:
- mTORC2信号通路是LUSC中的瘤免疫微环境的关键调节者.
- 针对mTORC2/PSGL-1/VISTA轴为LUSC.提供了一个有希望的治疗策略.
- 这种方法可能有利于那些对当前LUSC疗法没有反应的患者.
相关概念视频
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway
4.0K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
4.0K
Tumor Immunotherapy
665
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
665
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K


